// App-Quantinova.ai

355 : IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Jean H. Hoffman-Censits

Principal Investigators

  • Michiel Simon Van Der Heijden

  • Robert Dreicer

  • Yohann Loriot

  • Margitta Retz

  • Nicholas J. Vogelzang

  • Jose Luis Perez-Gracia

  • Arash Rezazadeh

  • Sergio Bracarda

  • Evan Y. Yu

  • Christopher J. Hoimes

  • Joaquim Bellmunt

  • David I. Quinn

  • Daniel Peter Petrylak

  • Syed A. Hussain

  • Na Cui

  • Sanjeev Mariathasan

  • Oyewale O. Abidoye

  • Jonathan E. Rosenberg

Medical Centers

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • University of Virginia school of medicine, Charlottesville, VA

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Department of Urology, Klinikum rechts der Isar, TU Munchen, Munich, Germany

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain

  • Norton Cancer Institute, Louisville, KY

  • Medical Oncology, Ospedale San Donato USL8, Istituto Toscano Tumori, Arezzo, Italy

  • University of Washington Seattle Cancer Care Alliance, Seattle, WA

  • Case - Seidman Cancer Ctr, Cleveland, OH

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Yale Cancer Center, New Haven, CT

  • University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • Genentech, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Netherlands

  • France

  • Germany

  • Spain

  • Italy

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • II

Study Id's

  • NCT02108652

  • NCT02302807

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved